MiMedx Group Inc. (NASDAQ:MDXG) shares traded up 2.5% on Wednesday . The stock traded as high as $7.30 and last traded at $7.24, with a volume of 459,606 shares trading hands. The stock had previously closed at $7.06.

Several research analysts recently weighed in on the stock. Brean Capital reissued a “buy” rating on shares of MiMedx Group in a research note on Wednesday, June 29th. Zacks Investment Research raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $10.89.

The stock has a 50 day moving average price of $7.55 and a 200 day moving average price of $7.88. The stock has a market capitalization of $798.91 million and a price-to-earnings ratio of 34.41.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Tuesday, July 26th. The company reported $0.05 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.02. The company earned $57 million during the quarter, compared to analyst estimates of $56.49 million. The firm’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.05 earnings per share. On average, equities analysts expect that MiMedx Group Inc. will post $0.23 earnings per share for the current fiscal year.

In related news, COO William Charles Taylor sold 24,333 shares of the firm’s stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $7.52, for a total transaction of $182,984.16. Following the completion of the transaction, the chief operating officer now owns 616,078 shares of the company’s stock, valued at $4,632,906.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

An institutional investor recently raised its position in MiMedx Group stock. Wells Fargo & Company MN increased its position in shares of MiMedx Group Inc. (NASDAQ:MDXG) by 19.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,041,546 shares of the company’s stock after buying an additional 169,102 shares during the period. Wells Fargo & Company MN owned 0.96% of MiMedx Group worth $9,759,000 at the end of the most recent quarter.

MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.